



**Dissemination and characteristics of a novel plasmid-encoded carbapenem-hydrolyzing class D -lactamase, OXA-436, found in isolates from four patients at six different hospitals in Denmark**

Samuelsen, Ørjan; Hansen, Frank; Aasnæs, Bettina; Hasman, Henrik; Lund, Bjarte Aarmo; Leiros, Hanna Kirsti S.; Lilje, Berit; Janice, Jessin; Jakobsen, Lotte; Littauer, Pia; Søres, Lillian M.; Holzkecht, Barbara J.; Andersen, Leif P.; Stegger, Marc; Andersen, Paal S.; Hammerum, Anette M.

*Published in:*  
Antimicrobial Agents and Chemotherapy

*DOI:*  
[10.1128/AAC.01260-17](https://doi.org/10.1128/AAC.01260-17)

*Publication date:*  
2018

*Document version*  
Publisher's PDF, also known as Version of record

*Document license:*  
[Unspecified](#)

*Citation for published version (APA):*  
Samuelsen, Ø., Hansen, F., Aasnæs, B., Hasman, H., Lund, B. A., Leiros, H. K. S., Lilje, B., Janice, J., Jakobsen, L., Littauer, P., Søres, L. M., Holzkecht, B. J., Andersen, L. P., Stegger, M., Andersen, P. S., & Hammerum, A. M. (2018). Dissemination and characteristics of a novel plasmid-encoded carbapenem-hydrolyzing class D -lactamase, OXA-436, found in isolates from four patients at six different hospitals in Denmark. *Antimicrobial Agents and Chemotherapy*, 62(1), [e01260-17]. <https://doi.org/10.1128/AAC.01260-17>



# Dissemination and Characteristics of a Novel Plasmid-Encoded Carbapenem-Hydrolyzing Class D $\beta$ -Lactamase, OXA-436, Found in Isolates from Four Patients at Six Different Hospitals in Denmark

Ørjan Samuelsen,<sup>a,b</sup> Frank Hansen,<sup>c</sup> Bettina Aasnaes,<sup>a</sup> Henrik Hasman,<sup>c</sup> Bjarte Aarmo Lund,<sup>d</sup> Hanna-Kirsti S. Leiros,<sup>d</sup> Berit Lilje,<sup>c</sup> Jessin Janice,<sup>a,e</sup> Lotte Jakobsen,<sup>c</sup> Pia Littauer,<sup>f</sup> Lillian M. Søres,<sup>g</sup> Barbara J. Holzknicht,<sup>g</sup> Leif P. Andersen,<sup>h</sup> Marc Stegger,<sup>c,i</sup> Paal S. Andersen,<sup>c,i,j</sup> Anette M. Hammerum<sup>c</sup>

<sup>a</sup>Norwegian National Advisory Unit on Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway

<sup>b</sup>Microbial Pharmacology and Population Biology Research Group, Department of Pharmacy, UiT, The Arctic University of Norway, Tromsø, Norway

<sup>c</sup>Department of Bacteria, Parasites, and Fungi, Statens Serum Institut, Copenhagen, Denmark

<sup>d</sup>The Norwegian Structural Biology Centre (NorStruct), Department of Chemistry, UiT, The Arctic University of Norway, Tromsø, Norway

<sup>e</sup>Research Group on Host-Microbe Interactions, Department of Medical Biology, UiT, The Arctic University of Norway, Tromsø, Norway

<sup>f</sup>Department of Clinical Microbiology, Hvidovre University Hospital, Hvidovre, Denmark

<sup>g</sup>Department of Clinical Microbiology, Slagelse Hospital, Slagelse, Denmark

<sup>h</sup>Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark

<sup>i</sup>Pathogen Genomics Division, Translational Genomics Research Institute (TGen), Flagstaff, Arizona, USA

<sup>j</sup>Veterinary Disease Biology, University of Copenhagen, Copenhagen, Denmark

**ABSTRACT** The diversity of OXA-48-like carbapenemases is continually expanding. In this study, we describe the dissemination and characteristics of a novel carbapenem-hydrolyzing class D  $\beta$ -lactamase (CHDL) named OXA-436. In total, six OXA-436-producing *Enterobacteriaceae* isolates, including *Enterobacter asburiae* ( $n = 3$ ), *Citrobacter freundii* ( $n = 2$ ), and *Klebsiella pneumoniae* ( $n = 1$ ), were identified in four patients in the period between September 2013 and April 2015. All three species of OXA-436-producing *Enterobacteriaceae* were found in one patient. The amino acid sequence of OXA-436 showed 90.4 to 92.8% identity to the amino acid sequences of other acquired OXA-48-like variants. Expression of OXA-436 in *Escherichia coli* and kinetic analysis of purified OXA-436 revealed an activity profile similar to that of OXA-48 and OXA-181, with activity against penicillins, including temocillin; limited or no activity against extended-spectrum cephalosporins; and activity against carbapenems. The *bla*<sub>OXA-436</sub> gene was located on a conjugative  $\sim 314$ -kb IncHI2/IncHI2A plasmid belonging to plasmid multilocus sequence typing sequence type 1 in a region surrounded by chromosomal genes previously identified to be adjacent to *bla*<sub>OXA</sub> genes in *Shewanella* spp. In conclusion, OXA-436 is a novel CHDL with functional properties similar to those of OXA-48-like CHDLs. The described geographical spread among different *Enterobacteriaceae* and the plasmid location of *bla*<sub>OXA-436</sub> illustrate its potential for further dissemination.

**KEYWORDS** carbapenems

**A**mbler class D  $\beta$ -lactamases constitute a large and diverse group of  $\beta$ -lactamases frequently identified among clinically relevant Gram-negative bacteria either as intrinsic chromosomally encoded  $\beta$ -lactamases in certain species or as acquired  $\beta$ -lactamases associated with mobile genetic elements (1, 2). In *Enterobacteriaceae*, the

Received 20 June 2017 Returned for  
modification 17 August 2017 Accepted 13  
October 2017

Accepted manuscript posted online 23  
October 2017

**Citation** Samuelsen Ø, Hansen F, Aasnaes B, Hasman H, Lund BA, Leiros H-KS, Lilje B, Janice J, Jakobsen L, Littauer P, Søres LM, Holzknicht BJ, Andersen LP, Stegger M, Andersen PS, Hammerum AM. 2018. Dissemination and characteristics of a novel plasmid-encoded carbapenem-hydrolyzing class D  $\beta$ -lactamase, OXA-436, found in isolates from four patients at six different hospitals in Denmark. Antimicrob Agents Chemother 62:e01260-17. <https://doi.org/10.1128/AAC.01260-17>.

**Copyright** © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to Anette M. Hammerum, ama@ssi.dk.

acquired carbapenem-hydrolyzing class D  $\beta$ -lactamases (CHDLs) have disseminated widely since the first identification of OXA-48 in a *Klebsiella pneumoniae* isolate (3) and have become the predominant carbapenemase type in many regions and countries (4). To date, several closely related OXA-48-like variants (e.g., OXA-48, OXA-162, OXA-163, OXA-181, OXA-204, OXA-232, OXA-244, OXA-245, OXA-247, OXA-370, and OXA-405) have been identified in clinically relevant *Enterobacteriaceae* (1, 5, 6). The *bla*<sub>OXA-48</sub>-like genes have been associated with different transposons formed by insertion sequences (IS), such as IS1999 and ISEcp1, and for *bla*<sub>OXA-48</sub>, an association with IncL plasmids has been described (1, 7, 8). Several studies have identified *Shewanella* spp., environmental waterborne bacteria, to be the natural host of *bla*<sub>OXA-48</sub>-like genes (9–11).

The amino acid sequence similarities between acquired OXA-48-like variants are high (>97%). In general, the hydrolytic activities of OXA-48-like enzymes are similar to those of other CHDLs, with activities against penicillins and carbapenems but no or limited activity against extended-spectrum cephalosporins (2, 12). The activity against carbapenems is variable but, in general, low, which, in the absence of additional mechanisms (i.e., membrane permeability defects), often results in a carbapenem-susceptible phenotype (12). Three variants, OXA-163, OXA-247, and OXA-405, deviate from this general profile, as they have clavulanic acid-inhibited activity against extended-spectrum cephalosporins and even lower or negligible activity against carbapenems (6, 13, 14).

In this study, we describe a novel plasmid-mediated OXA-48 variant named OXA-436 initially discovered in an *Enterobacter asburiae* isolate recovered from a patient admitted to a hospital in the Capital Region of Denmark and subsequently detected in isolates from three other patients in Denmark, including other *Enterobacteriaceae*.


## RESULTS AND DISCUSSION

**Epidemiological setting and identification of *bla*<sub>OXA-436</sub>.** In September 2013, an *E. asburiae* isolate (AMA 497) intermediate susceptible to meropenem was detected from a urine sample from a patient (patient 1) (Table 1). In January 2014, a second *E. asburiae* isolate (AMA 590), also intermediate susceptible to meropenem, was detected from another patient (patient 2) at another hospital. Both isolates were positive for carbapenemase production by the Carba NP test, and the phenotypic data indicated the presence of a class D carbapenemase (see below). However, the isolates were negative for *bla*<sub>OXA-48</sub> by using previously described internal primers (3), as well as negative for genes encoding other known carbapenemases, *bla*<sub>VIM</sub>, *bla*<sub>IMP</sub>, *bla*<sub>GIM</sub>, *bla*<sub>SPM</sub>, *bla*<sub>SIM</sub>, *bla*<sub>NDM</sub>, and *bla*<sub>KPC</sub>, by PCR. In order to identify the carbapenemase, the isolates were subjected to whole-genome sequencing (WGS), and the sequence data (15) were analyzed using the ResFinder program (16), which indicated the presence of a gene for a  $\beta$ -lactamase with 88% nucleotide sequence similarity to *bla*<sub>OXA-181</sub> (15). Subsequent analysis of the nucleotide sequence and comparison of its nucleotide sequence with the nucleotide sequences of the genes for other OXA-48-like variants showed that it encoded a class D  $\beta$ -lactamase with close similarity to other OXA-48-like variants and was designated OXA-436 (Fig. 1). A new PCR for the detection of *bla*<sub>OXA-436</sub> was subsequently developed and integrated into the PCR analysis of isolates suspected of harboring a carbapenemase submitted to the Danish National Reference Laboratory. Subsequently, four isolates recovered from two other patients in the period between August 2014 and April 2015 were PCR positive for *bla*<sub>OXA-436</sub> (Table 1).

In August 2014, a *bla*<sub>OXA-436</sub> PCR-positive *Citrobacter freundii* isolate was detected from a third patient (patient 3). During October and November 2014, a *bla*<sub>OXA-436</sub>-positive *K. pneumoniae* isolate and a *bla*<sub>OXA-436</sub>-positive *E. asburiae* isolate were detected from patient 3. In April 2015, a *bla*<sub>OXA-436</sub>-positive *C. freundii* isolate (AMA 948) was recovered from a fourth patient (patient 4). The three *E. asburiae* isolates had highly similar single nucleotide polymorphism (SNP) profiles (4 to 15 SNP differences), indicating clonal spread. In contrast, the two *C. freundii* isolates belonged to two different sequence types (STs; ST22 and ST65) and had very different SNP profiles (>29,000 SNP differences) (Table 1), indicating independent events of plasmid transfer.

**TABLE 1** Description of the six *bla*<sub>OXA-436</sub>-positive isolates from four patients

| Patient no. | Species              | Reference designation | Sample collection date | Hospital | Specimen      | MLST ST | SNP profile                          | β- Lactamases   | Other resistance genes  |
|-------------|----------------------|-----------------------|------------------------|----------|---------------|---------|--------------------------------------|---|---|
| 1           | <i>E. asburiae</i>   | AMA 497               | Sept. 2013             | A        | Urine         |         |                                      | <i>bla</i> <sub>ACT-6-like</sub> <sup>r</sup> <i>bla</i> <sub>OXA-10</sub> <sup>r</sup> <i>bla</i> <sub>SHV-12</sub> <sup>r</sup>                               | <i>strA</i> , <i>strB</i> , <i>aac</i> (6')-IIc, <i>aadA1</i> , <i>aadA2</i> , <i>qnrA1</i> , <i>sul1</i> , <i>sul2</i> , <i>dfrA18</i> |
| 2           | <i>E. asburiae</i>   | AMA 590               | Jan. 2014              | B        | Urine         |         | 4 SNP differences from AMA 497       | <i>bla</i> <sub>ACT-6-like</sub> <sup>r</sup> <i>bla</i> <sub>OXA-10</sub> <sup>r</sup> <i>bla</i> <sub>SHV-12</sub> <sup>r</sup>                               | <i>strA</i> , <i>strB</i> , <i>aac</i> (6')-IIc, <i>aadA1</i> , <i>aadA2</i> , <i>qnrA1</i> , <i>sul1</i> , <i>sul2</i> , <i>dfrA18</i> |
| 3           | <i>C. freundii</i>   | AMA 754               | Aug. 2014              | C        | Pleural fluid | ST65    |                                      | <i>bla</i> <sub>TEM-1b</sub> <i>bla</i> <sub>CMY-48-like</sub> <sup>r</sup> <i>bla</i> <sub>OXA-10</sub> <sup>r</sup> <i>bla</i> <sub>SHV-12</sub> <sup>r</sup> | <i>strA</i> , <i>strB</i> , <i>aac</i> (6')-IIc, <i>aadA1</i> , <i>aadA2</i> , <i>qnrA1</i> , <i>sul1</i> , <i>sul2</i> , <i>dfrA18</i> |
| 3           | <i>K. pneumoniae</i> | AMA 782               | Oct. 2014              | D        | Pleural fluid | ST35    |                                      | <i>bla</i> <sub>SHV-1</sub> <i>bla</i> <sub>TEM-1b</sub> <i>bla</i> <sub>OXA-10</sub> <sup>r</sup> <i>bla</i> <sub>SHV-12</sub> <sup>r</sup>                    | <i>strA</i> , <i>strB</i> , <i>aac</i> (6')-IIc, <i>aadA1</i> , <i>aadA2</i> , <i>qnrA1</i> , <i>sul1</i> , <i>sul2</i> , <i>dfrA18</i> |
| 3           | <i>E. asburiae</i>   | AMA 810               | Nov. 2014              | E        | Expectorate   |         | 15 SNP differences from AMA 497      | <i>bla</i> <sub>ACT-6-like</sub> <sup>r</sup> <i>bla</i> <sub>OXA-10</sub> <sup>r</sup> <i>bla</i> <sub>SHV-12</sub> <sup>r</sup>                               | <i>strA</i> , <i>strB</i> , <i>aac</i> (6')-IIc, <i>aadA1</i> , <i>aadA2</i> , <i>qnrA1</i> , <i>sul1</i> , <i>sul2</i> , <i>dfrA18</i> |
| 4           | <i>C. freundii</i>   | AMA 948               | Apr. 2015              | F        | Urine         | ST22    | >29,000 SNP differences from AMA 754 | <i>bla</i> <sub>CMY-48-like</sub> <sup>r</sup> <i>bla</i> <sub>OXA-10</sub> <sup>r</sup> <i>bla</i> <sub>SHV-12</sub> <sup>r</sup> <i>bla</i> <sub>TEM-1b</sub> | <i>strA</i> , <i>strB</i> , <i>aac</i> (6')-IIc, <i>aadA1</i> , <i>aadA2</i> , <i>qnrA1</i> , <i>sul1</i> , <i>sul2</i> , <i>dfrA18</i> |



**FIG 1** (A) Phylogenetic tree based on amino acid sequences showing the relationship of OXA-436, acquired OXA-48-like variants, and selected OXA-48-like variants from *Shewanella* spp. The tree is rooted at the midpoint. OXA-48-like variants devoid of carbapenemase activity are indicated with asterisks. (B) Alignment of the amino acid sequence of OXA-436 with the amino acid sequences of selected OXA-48-like variants. Conserved motifs are shaded in black. The secondary structural elements of OXA-48 are indicated above the sequences.

All six OXA-436-producing isolates were from clinical specimens and were from six different hospitals (Table 1). Unfortunately, none of the hospitals screened the patients by collection of a rectal swab sample for outbreak investigation. A retrospective analysis of selected isolates submitted prior to the first identification of *bla*<sub>OXA-436</sub> was performed but revealed no *bla*<sub>OXA-436</sub>-positive isolates. None of the four patients with OXA-436-producing isolates had recently traveled abroad, and the origin of the *bla*<sub>OXA-436</sub> gene remains unknown.

**Phenotypic profiles and molecular characteristics of *bla*<sub>OXA-436</sub>-positive isolates.** The antimicrobial susceptibility profiles of the *bla*<sub>OXA-436</sub>-positive isolates are summarized in Table 2. All isolates were resistant to penicillins (including high-level resistance to temocillin), extended-spectrum cephalosporins, and aztreonam. Furthermore, all isolates were resistant to ertapenem but were either susceptible or intermediately susceptible to meropenem and imipenem. Nonsusceptibility to gentamicin, tobramycin, ciprofloxacin, and trimethoprim-sulfamethoxazole was also observed. All isolates retained susceptibility to ceftazidime-avibactam, colistin, amikacin, and tigecycline, except for the *C. freundii* isolate, which was intermediately susceptible to tigecycline. The non- $\beta$ -lactam  $\beta$ -lactamase inhibitor avibactam has been shown to be a potent inhibitor of class A, class C, and certain class D enzymes (17). To assess the inhibitory properties of avibactam on OXA-436, determination of the MICs of temocillin and meropenem with and without avibactam were performed since OXA-48-like enzymes have limited or no activity against ceftazidime (12) and since the strains carried multiple other  $\beta$ -lactamases. For the clinical isolates, the additive inhibitory effect of 4 mg/liter avibactam reduced the temocillin MIC 16- to 32-fold and the meropenem MIC 16- to 64-fold. For the cloned OXA-436-producing *Escherichia coli* TOP10 isolate, the temocillin MIC was reduced 16-fold; however, the lower endpoint of the test range for meropenem allowed only a  $\geq 2$ -fold MIC reduction to be observed. The results of phenotypic synergy tests for  $\beta$ -lactamase-mediated resistance were either inconclusive or negative, with the exception of positive test results for extended-spectrum  $\beta$ -lactamases (ESBLs) (data not shown). No synergy between meropenem and boronic acid, dipicolinic acid, or cloxacillin was observed. In addition, no zone diameter was

**TABLE 2** Antimicrobial susceptibility profiles of six clinical isolates, an *E. coli* J53A transconjugant of AMA 754 (AMA 1292), and *E. coli* J53A and  $\beta$ -lactam susceptibilities of *E. coli* TOP10 expressing  $\beta$ -lactamases and *E. coli* TOP10


| MIC (mg/liter)                |                               |                               |                               |                                 |                               |                               |   |                          |   |  |   |                         |  |
|-------------------------------|-------------------------------|-------------------------------|-------------------------------|---------------------------------|-------------------------------|-------------------------------|---|--------------------------|---|--|---|-------------------------|--|
| Antibiotic                    | <i>E. asburiae</i><br>AMA 497 | <i>E. asburiae</i><br>AMA 590 | <i>C. freundii</i><br>AMA 754 | <i>K. pneumoniae</i><br>AMA 782 | <i>E. asburiae</i><br>AMA 810 | <i>C. freundii</i><br>AMA 948 | <i>E. coli</i><br>AMA 1292 <sup>a</sup> | <i>E. coli</i><br>J53A3R | <i>E. coli</i> TOP10<br>(pCR-BluntII-<br>OXA-436) | <i>E. coli</i> TOP10<br>(pCR-BluntII-<br>OXA-48) | <i>E. coli</i> TOP10<br>(pCR-BluntII-<br>OXA-181) | <i>E. coli</i><br>TOP10 |  |
| Temocillin                    | >256                          | >256                          | >256                          | >256                            | >256                          | >256                          | >256                                    | 8                        | >256  | >256   | >256  | 16                      |  |
| Piperacillin-tazobactam       | >64                           | >64                           | >64                           | >64                             | >64                           | >64                           | >64                                     | 2                        | >64   | >64  | >64   | 2                       |  |
| Ceftazidime                   | >32                           | >32                           | 32                            | >32                             | >32                           | >32                           | >32                                     | 0.25                     | 0.5   | 1  | 1   | 0.5                     |  |
| Ceftazidime-avibactam         | 0.5                           | 0.25                          | 0.5                           | 0.5                             | 0.25                          | 1                             | 0.5                                     | 0.125                    | 0.25  | 0.5  | 1   | 0.25                    |  |
| Cefotaxime                    | 8                             | 8                             | 8                             | 4                               | 8                             | >16                           | 4                                       | ≤0.06                    | 0.125   | 1  | 2   | 0.125                   |  |
| Cefoxitin                     | >32                           | >32                           | >32                           | 16                              | >32                           | >32                           | 16                                      | 8                        | 16  | 16   | 32  | 4                       |  |
| Aztreonam                     | >16                           | >16                           | >16                           | >16                             | >16                           | >16                           | >16                                     | ≤0.125                   | ≤0.125  | 0.25   | 0.25  | ≤0.125                  |  |
| Meropenem                     | 4                             | 4                             | 1                             | 2                               | 4                             | 1                             | 1                                       | 0.032                    | 0.5   | 1  | 1   | 0.032                   |  |
| Imipenem                      | 4                             | 4                             | 2                             | 2                               | 4                             | 2                             | 2                                       | 0.25                     | 2   | 2  | 2   | 0.25                    |  |
| Ertapenem                     | >4                            | 4                             | 4                             | >4                              | >4                            | 4                             | 4                                       | ≤0.015                   | 1   | 2  | 2   | ≤0.015                  |  |
| Gentamicin                    | 128                           | 128                           | 64                            | 128                             | 64                            | 64                            | 32                                      | ≤0.25                    | ND <sup>b</sup>                                   | ND   | ND  | ND                      |  |
| Amikacin                      | <1                            | <1                            | <1                            | <1                              | <1                            | <1                            | <1                                      | <1                       | ND  | ND   | ND  | ND                      |  |
| Tobramycin                    | 4                             | 8                             | 8                             | 8                               | 8                             | 4                             | 2                                       | <0.5                     | ND  | ND   | ND  | ND                      |  |
| Ciprofloxacin                 | 4                             | 4                             | 8                             | 16                              | 4                             | 2                             | 0.5                                     | <0.015                   | ND  | ND   | ND  | ND                      |  |
| Tigecycline                   | 0.5                           | 0.5                           | 2                             | 1                               | 1                             | 0.5                           | 0.25                                    | 0.25                     | ND  | ND   | ND  | ND                      |  |
| Colistin                      | 0.5                           | 0.5                           | 1                             | 0.5                             | 0.5                           | 1                             | ≤0.25                                   | 0.5                      | ND  | ND   | ND  | ND                      |  |
| Trimethoprim-sulfamethoxazole | >16                           | >16                           | >16                           | >16                             | >16                           | >16                           | >16                                     | >16                      | ND  | ND   | ND  | ND                      |  |

<sup>a</sup>AMA 1292 is the *E. coli* J53A transconjugant of AMA 754.<sup>b</sup>ND, not determined.



observed with temocillin, indicating the presence of an OXA-48-like carbapenemase (18). All isolates were Carba NP test positive, illustrating the usefulness of this method for the detection of novel carbapenemases. Although some studies have reported problems with the low sensitivity of this test for OXA enzymes (19, 20), the enzyme activity of OXA-436 was sufficient for a positive Carba NP test result, and positive reactions were observed in <30 min. Similarly, positive test results were also obtained for all six study isolates by a novel immunochromatographic test (OXA-48 K-SeT; Coris BioConcept) for the detection of OXA-48-like enzymes. This showed that the monoclonal anti-OXA-48 antibodies incorporated in this lateral flow-based test also bind to the OXA-436-containing conjugate.

**Genetic context of *bla*<sub>OXA-436</sub>.** The identification of *bla*<sub>OXA-436</sub> in different species, including the identification of three different *bla*<sub>OXA-436</sub>-positive species from the same patient (patient 3), indicated that *bla*<sub>OXA-436</sub> is plasmid borne and that transfer can occur *in vivo*. Further, the identification of a common set of acquired resistance genes (Table 1) among the isolates indicated colocalization on the same mobile genetic element. Replicon identification using the PlasmidFinder web tool also showed the presence of IncHI2 and IncHI2A replicons in all strains. *In vitro* plasmid transfer experiments supported the plasmid localization of *bla*<sub>OXA-436</sub>, as transconjugants were obtained from three donor strains (*C. freundii* AMA 754, *K. pneumoniae* AMA 782, and *E. asburiae* AMA 810). This was confirmed by combined single-molecule real-time (SMRT; PacBio) and MiSeq (Illumina) sequencing to generate a circular plasmid (designated pOXA436) genome of 314,137 bp (Fig. 2A) harboring *bla*<sub>OXA-436</sub>. pOXA436 were found to be an IncHI2 plasmid belonging to ST1 according to the plasmid double-locus sequence typing scheme for IncHI2 plasmids (21). Comparison of pOXA436 with other IncHI2 plasmids showed the presence of the common backbone found in other IncHI2 plasmids (see, e.g., references 21, 22, 23, 24), including the replicon IncHI2, transfer regions Tra1 and Tra2, a partitioning system, and regions conferring resistance to heavy metals (tellurite, mercury, and arsenic). IncHI2 plasmids have previously been associated with a large number of various antibiotic resistance genes, including genes for carbapenemases, such as *bla*<sub>VIM</sub>, *bla*<sub>IMP</sub>, and *bla*<sub>NDM</sub> (21, 25). In pOXA436, the antibiotic resistance genes were located in two separate regions of the plasmid (Fig. 2A). In contrast to the neighboring genetic structures of *bla*<sub>OXA-48</sub>-like genes identified in *Enterobacteriaceae*, which are closely associated with IS elements, such as IS1999 and ISEcp1 (1), the *bla*<sub>OXA-436</sub> gene was located in a region of >7,300 bp surrounded by chromosomal genes previously identified to be adjacent to *bla*<sub>OXA</sub> genes in *Shewanella* (9). This region included an open reading frame encoding a hypothetical protein and the *sprT* gene, encoding a protein of unknown function, upstream of *bla*<sub>OXA-436</sub>. Downstream of *bla*<sub>OXA-436</sub>, a gene encoding a putative LysR-type transcriptional regulator was followed by a truncated *acc* gene encoding a carbamoyl phosphate synthase. Overall, this region showed high nucleotide sequence similarity (96%) with the chromosomal region in *Shewanella* sp. strains MR-4 and MR-7, isolated from the Black Sea; *Shewanella* sp. strain ANA-3, isolated from arsenic-treated wood in a brackish estuary in the United States (26); and a clinical *Shewanella bicestris* sp. nov. isolate, JAB-1 (GenBank accession number CP022358). The species of strains MR-4, MR-7, and ANA-3 have not been determined, but genome analysis indicates that these could represent new *Shewanella* species (26). Interestingly, a novel OXA-48-like enzyme, OXA-535, with 98.9% amino acid sequence identity to OXA-436 was identified in *Shewanella bicestris* sp. nov. strain JAB-1 (27), suggesting that this might be the original host and that *bla*<sub>OXA-535</sub> is the progenitor of *bla*<sub>OXA-436</sub>. The exact mechanism behind the mobilization of the *bla*<sub>OXA-436</sub> region onto the pOXA436 plasmid is unclear. However, two IS91 family-like IS elements (ISCR1) were identified upstream of the *bla*<sub>OXA-463</sub> region and one was identified downstream of the *bla*<sub>OXA-463</sub> region, and these elements could have been involved in the mobilization of the *bla*<sub>OXA-436</sub> region onto the pOXA436 plasmid (Fig. 2B). The transposase genes of all three IS91-like/ISCR1 elements were



**FIG 2** (A) Circular map of pOXA436 (GenBank accession number [KY863418](#)) drawn using CGView (47). The two outer circles show predicted open reading frames, with selected genes indicated according to gene function (see the key for the color scheme). The next four circles show homology to other IncH12 plasmids: R478 (GenBank accession number [BX664015](#)), pH11 (GenBank accession number [CP013215](#)), pK29 (GenBank accession number [EF382672](#)), and pEC\_IMP (GenBank accession number [EU855787](#)). (B) Linear representation of the genetic structure surrounding the *bla*<sub>OXA-436</sub> region in pOXA436. Arrows represent open reading frames and the direction of transcription. Horizontal dotted lines mark the boundaries of the region with a high level of identity to *Shewanella* isolates MR-4 (GenBank accession number [CP000446](#)), MR-7 (GenBank accession number [CP000444](#)), and ANA-3 (GenBank accession number [CP000469](#)) and *S. bicestris* sp. nov. JAB-1 (GenBank accession number [CP022358](#)). The nucleotide positions of the fragment in relation to the pOXA436 sequence are indicated.



**TABLE 3** Kinetic parameters of OXA-436 compared to OXA-48 and OXA-181

| Substrate        | $K_m$ ( $\mu\text{M}$ ) |                     |                      | $k_{\text{cat}}$ ( $\text{s}^{-1}$ ) |                     |                      | $k_{\text{cat}}/K_m$ ( $\mu\text{M}^{-1} \cdot \text{s}^{-1}$ ) |                     |                      |
|------------------|-------------------------|---------------------|----------------------|--------------------------------------|---------------------|----------------------|---|---------------------|----------------------|
|                  | OXA-436                 | OXA-48 <sup>a</sup> | OXA-181 <sup>b</sup> | OXA-436                              | OXA-48 <sup>a</sup> | OXA-181 <sup>b</sup> | OXA-436   | OXA-48 <sup>a</sup> | OXA-181 <sup>b</sup> |
| Benzylpenicillin | 200 $\pm$ 100           | 79                  | 90                   | 900 $\pm$ 100                        | 446                 | 444                  | 4.5   | 5.6                 | 5.0                  |
| Ampicillin       | 5 $\pm$ 1               | 395                 | 170                  | 600 $\pm$ 40                         | 955                 | 218                  | 120   | 2.4                 | 1.3                  |
| Temocillin       | 200 $\pm$ 100           | 45                  | 60                   | 3 $\pm$ 1                            | 0.3                 | 0.3                  | 0.015   | 0.0066              | 0.005                |
| Cefotaxime       | 130 $\pm$ 20            | 190                 | >1000                | 6 $\pm$ 0.4                          | 10                  | >62                  | 0.046   | 0.06                | 0.013                |
| Ceftazidime      | 150 $\pm$ 50            | 5100                | NH <sup>c</sup>      | 7 $\pm$ 1                            | 4                   | ND <sup>d</sup>      | 0.047   | 0.001               | ND                   |
| Imipenem         | 20 $\pm$ 1              | 13                  | 13                   | 6 $\pm$ 0.2                          | 4.8                 | 7.5                  | 0.3   | 0.37                | 0.55                 |
| Meropenem        | 3 $\pm$ 1               | 11                  | 70                   | 0.14 $\pm$ 0.01                      | 0.07                | 0.1                  | 0.047   | 0.0062              | 0.0015               |
| Ertapenem        | 160 $\pm$ 60            | 100                 | 100                  | 0.4 $\pm$ 0.05                       | 0.13                | 0.2                  | 0.0025  | 0.0013              | 0.002                |

<sup>a</sup>Kinetic parameters for OXA-48 are from Docquier et al. (28), except for those for benzylpenicillin, which are from Antonelli et al. (29), and cefotaxime-ceftazidime, which are from Poirel et al. (3).

<sup>b</sup>Kinetic parameters for OXA-181 are from Oueslati et al. (12).

<sup>c</sup>NH, no detectable hydrolysis.

<sup>d</sup>ND, not determined.

identical at the amino acid level, and their amino acid sequences were identical to the amino acid sequence with GenBank accession number [WP\\_000050481](http://www.ncbi.nlm.nih.gov/nuclot/000050481).

The antimicrobial susceptibility of one representative transconjugant (AMA 1292) showed the expected profile according to the resistance genes present on pOXA436 (Table 2).

**Characterization of OXA-436.** Analysis of the OXA-436 amino acid sequence showed that, in contrast to the limited differences ( $\geq 97.4\%$  amino acid sequence similarity) between previously described acquired OXA-48-like variants, the amino acid sequence of OXA-436 showed only 90.4 to 92.8% similarity to the amino acid sequences of the acquired OXA-48-like variants (Fig. 1). However, a greater amino acid sequence similarity (97.7 to 98.5%) to the amino acid sequences of *bla*<sub>OXA-48</sub>-like genes from *Shewanella* isolates MR-4, MR-7, ANA-3, and JAB-1 (GenBank accession numbers [CP000446](http://www.ncbi.nlm.nih.gov/nuclot/CP000446), [CP000444](http://www.ncbi.nlm.nih.gov/nuclot/CP000444), [CP000469](http://www.ncbi.nlm.nih.gov/nuclot/CP000469), and [CP022358](http://www.ncbi.nlm.nih.gov/nuclot/CP022358), respectively) was observed (9). This may indicate that the *Shewanella* species that is the natural host of *bla*<sub>OXA-436</sub> is different from the *Shewanella* species that is the natural host of *bla*<sub>OXA-48</sub> and *bla*<sub>OXA-181</sub>, which has been identified to be *Shewanella xiamenensis* (9, 11). Subsequent cloning and expression of *bla*<sub>OXA-436</sub>, *bla*<sub>OXA-48</sub>, and *bla*<sub>OXA-181</sub> in *E. coli* TOP10 showed that OXA-436 produced the characteristic profile of OXA-48-like carbapenemases (12), resulting in a significant increase ( $>2$ -fold) in the MICs of penicillins and carbapenems and no significant change in the MICs of extended-spectrum cephalosporins and monobactams (aztreonam) (Table 2). The values of the kinetic parameters determined were also in broad agreement with the *in vitro* susceptibility data (Table 2) and were similar to the previously determined values of the kinetic parameters of OXA-48 (3, 28, 29) and OXA-181 (12) (Table 3). As shown for other OXA-48-like carbapenemases, the activity of OXA-436 against extended-spectrum cephalosporins was limited. Measurable activity of OXA-436 against ceftazidime ( $k_{\text{cat}}/K_m$ , 0.047  $\mu\text{M}^{-1} \cdot \text{s}^{-1}$ ) was observed, and this activity was slightly higher than that initially described for OXA-48 ( $k_{\text{cat}}/K_m$ , 0.001  $\mu\text{M}^{-1} \cdot \text{s}^{-1}$ ) (3), mainly due to the lower  $K_m$ . Activity against ceftazidime has been described for OXA-48-like variants, such as OXA-163 and OXA-232 (12). However, for OXA-163 and OXA-232, this has been at the expense of reduced activity against carbapenems and temocillin (OXA-232) (12). As the hydrolytic activity against ceftazidime did not result in a change in the MIC for *E. coli* TOP10 in the susceptibility assay (Table 2), this could indicate that the activity is observed only *in vitro* or that the *in vitro* activity is too low to contribute to activity *in vivo*. In contrast to previously published kinetic data, the kinetic assay for OXA-436 was performed in the presence of sodium bicarbonate, as  $\text{CO}_2$  is required for *N*-carboxylation of the catalytic lysine (30). However, experiments without sodium bicarbonate showed similar results (data not shown), with measurable hydrolytic activity against ceftazidime being found. Investigation of the changes in the amino acid composition of OXA-436 in light of the three-dimensional structure

of OXA-48 clearly showed that most mutations were at the protein surface, as would be expected for random mutations, because the inner core of enzymes is more conserved (31). The two buried residues Ile226 (similar to OXA-48 Val226) and Thr237 (Met237 in OXA-48), localized to the  $\beta$ 7 sheet (28), are common residues in  $\beta$  sheets. Since the majority of the changes are localized at the surface in the three-dimensional structure of OXA-48, it seems likely that there would be no major changes to the overall fold of the OXA-436 structure compared to that of the OXA-48 structure. We believe that this is reflected in the similar functional characteristics of the two enzymes (Table 3). We are currently determining the crystal structure of OXA-436.

**Conclusions.** OXA-48 and OXA-48-like variants have become the dominant carbapenemases among *Enterobacteriaceae* in several regions and epidemiological settings (4). In this study, we identified a novel OXA-48-like variant named OXA-436 with higher amino acid sequence divergence from the currently identified OXA-48-like variants than the other OXA-48-like variants, whose sequences are closely related. Despite this divergence, OXA-436 shows broadly the same functional properties as other OXA-48-like variants with carbapenemase and penicillinase activity. The high degree of amino acid sequence similarity of OXA-436 with the amino acid sequences of OXA-48-like variants in members of the genus *Shewanella* whose species have so far not been determined further underlines the importance of species of this genus as the reservoir for OXA-48-like variants. The identification of *bla*<sub>OXA-436</sub> in three different *Enterobacteriaceae* species and four patients indicates the potential for further dissemination. The increased divergence of OXA-48-like variants complicates molecular-based detection and shows the importance of phenotypic and biochemical methods for the detection of carbapenemases.

## MATERIALS AND METHODS

**Bacterial strains.** Six clinical isolates from four hospitalized patients were submitted to the Reference Laboratory for Antimicrobial Resistance and Staphylococci at the Statens Serum Institut in Copenhagen, Denmark, as part of the national surveillance for carbapenemase-producing organisms (approved by the Danish Data Protection Agency [no. 2015-57-0102]). Species identification was initially performed using matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS; Bruker Daltonik, Bremen, Germany) and subsequently using the whole-genome sequence data described below. *Escherichia coli* TOP10 (Invitrogen, CA, USA) was used as the host strain for the cloning and expression of *bla*<sub>OXA-436</sub>, *bla*<sub>OXA-48</sub>, and *bla*<sub>OXA-181</sub>. *E. coli* J53A3R was used for mating experiments. *bla*<sub>OXA-48</sub> and *bla*<sub>OXA-181</sub> were obtained from previously described strains (32).

**Antimicrobial susceptibility testing, phenotypic analysis, and initial PCR screening.** MIC determinations were performed by broth microdilution using in-house-designed premade Sensititre microtiter plates (Trek Diagnostic Systems/Thermo Fisher Scientific, East Grinstead, UK). The MICs of the combination of temocillin (Eumedica, Basel, Switzerland) and meropenem (Hospira, Lake Forest, IL, USA) with avibactam (AstraZeneca, Cheshire, UK) were determined using the CLSI broth microdilution MIC methodology (33). Susceptibility patterns were interpreted according to the clinical breakpoints defined by EUCAST (version 7.1; [http://www.eucast.org/clinical\\_breakpoints/](http://www.eucast.org/clinical_breakpoints/)). Combination gradient strips and discs for phenotypic detection of extended-spectrum  $\beta$ -lactamases (ESBLs; Becton Dickinson, Sparks, MD, USA/Liofilchem), AmpC  $\beta$ -lactamases (Rosco Diagnostica, Taastrup, Denmark/Liofilchem), and carbapenemases (Rosco Diagnostica) were performed according to the manufacturers' instructions. The Carba NP test was performed as previously described (34), and the OXA-48 K-SeT test (Coris BioConcept, Gembloux, Belgium) was performed according to the manufacturer's instructions. Initial PCR screening for carbapenemase-encoding genes was performed using assays previously described for the detection of *bla*<sub>VIM</sub>, *bla*<sub>IMP</sub>, *bla*<sub>GIM</sub>, *bla*<sub>SPM</sub>, *bla*<sub>SIM</sub>, *bla*<sub>NDM</sub>, *bla*<sub>KPC</sub>, and *bla*<sub>OXA-48</sub> (3, 35, 36).

**Whole-genome sequencing (WGS) and sequence analysis.** Genomic DNA was extracted from carbapenemase-producing isolates using a DNeasy blood and tissue kit (Qiagen, Hilden, Germany). Fragment libraries were constructed using a Nextera kit (Illumina, Little Chesterford, UK), followed by 251-bp paired-end sequencing (MiSeq; Illumina), according to the manufacturers' instructions. Paired-end sequence data were assembled using CLCbio's Genomics Workbench (version 8.0; Qiagen, Aarhus, Denmark).

The sequence reads from the *Citrobacter freundii* and *Enterobacter asburiae* isolates were aligned against the reference genomes of *C. freundii* CFNIH1 (GenBank accession number [NZ\\_CP007557](#)) and *E. asburiae* L1 (GenBank accession number [NZ\\_CP007546](#)), respectively, using the short-read alignment component of the Burrows-Wheeler aligner (BWA) (37). Using the Northern Arizona SNP Pipeline (<http://tgennorth.github.io/NASP/>), identification of SNP variants was performed using the GATK UnifiedGenotyper with filtering set to remove positions with less than 10 $\times$  coverage and <90% unambiguous variant calls after positions within duplicated regions of the reference sequence were removed using the NUCmer program (38). Phylogenetic analysis of the identified SNPs was performed using

maximum parsimony implemented in MEGA (version 6.0.6) software (39). Comparison of the sequences was performed using CLCbio's Genomics Workbench (version 8.0; Qiagen).

The web servers of ResFinder (version 2.1), PlasmidFinder (*Enterobacteriaceae*) (version 1.2), pMLST (Inchi2; version 1.4), and MLST (version 1.7) at <http://www.genomicepidemiology.org/> were used to identify acquired antimicrobial resistance genes, plasmid replicon types, the plasmid multilocus sequence types (pMLST), and multilocus sequence types (MLST) from the assembled WGS data, respectively (16, 40, 41). For resistance genes, a threshold of 100% identity was used for the genes encoding  $\beta$ -lactamases, and 98% identity was used for all other genes. A lower identity threshold (60%) was initially used to search for putative novel  $\beta$ -lactamase genes.

Species identification using WGS data for the *Enterobacter* isolates was performed using phylogenetic analysis of fragments of the two housekeeping genes *rpoB* and *hsp60* as described by Paaup et al. (42). Comparisons of the sequences of contigs containing *bla*<sub>OXA-436</sub> were done using BLAST analysis (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>). The amino acid sequences of acquired OXA-48-like variants and selected OXA-48-like variants were obtained from the NCBI Bacterial Antimicrobial Resistance Reference Gene Database (BioProject accession number [PRJNA313047](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA313047)). Alignment and construction of a phylogenetic tree of OXA-48-like variants were done in the RAXML (version 8.2.8) program (43) using the MAFFT (version 7.305b) program (44) with a bootstrap of 100 replicates. A structural amino acid sequence alignment was created using the ESript (version 3.0) program (<http://esript.ibcp.fr/ESript/ESript/>) (45).

A complete plasmid DNA sequence was obtained from a genome extracted from *E. asburiae* AMA 497 (Table 1) using a Genomic-tip 500/G kit (Qiagen, Hilden, Germany), which was used to prepare a 20-kb library for sequencing on a Pacific Biosciences RS II instrument using P6-C4 chemistry with a 360-min moving time on one single-molecule real-time (SMRT) cell (Pacific Biosciences, Menlo Park, CA) to generate 90,579 reads for a total of 1,503 Mb. Initial scaffolding was performed using HGAP (version 3) (SMRT analysis software, version 2.3.0; Pacific Biosciences) to give an average base coverage of 133 $\times$ . The paired-end MiSeq data from AMA 497 described above were used for error correction and finalization of the sequencing data. The assembled plasmid sequence was annotated with the Prokka software tool (46) and manually curated for accuracy. A circular plasmid map was drawn using the CGView program (47).

**Cloning, expression, and purification.** For expression and purification of OXA-436, *bla*<sub>OXA-436</sub> was amplified using forward (5'-ATAATTTTGTAACTTTAAGAGGAGATATACATATGCGTGCCTTAGCCTTA-3') and reverse (5'-CTTTGTTAGCAGCTCGAATCACTAAGGAATAATTTTCTGTTTCAG-3') primers. The primers contain overlaps with pDEST17 (Invitrogen, CA, USA), and *bla*<sub>OXA-436</sub> with the signal peptide was cloned into pDEST17 using restriction-free cloning as previously described (48). The purified plasmid was transformed into *E. coli* BL21 Star(DE3)pRARE cells (49) and expressed in ZYP5052 (50) cultures containing 100  $\mu$ g/ml ampicillin and 34  $\mu$ g/ml chloramphenicol. OXA-436 was isolated from the periplasm and purified by anion-exchange chromatography as described previously (51). The protein identity was confirmed by mass spectrometry.

For functional resistance profile analysis, cloning and expression of *bla*<sub>OXA-436</sub>, *bla*<sub>OXA-48r</sub>, and *bla*<sub>OXA-181</sub> in an isogenic *E. coli* background were performed using a pCR-BluntII-TOPO cloning kit (Invitrogen, CA, USA). PCR fragments containing the entire sequences of the *bla*<sub>OXA</sub> genes were obtained by PCR using Phusion high-fidelity PCR Mastermix with high-fidelity buffer (New England BioLabs, MA, USA) and the following primer pairs: OXAP18-15A (5'-TTTATTGCATTAGGCAAGGG-3')/OXAP18-15B (5'-TACACAAATGC GCGCTAAC-3') for *bla*<sub>OXA-436</sub> and preOXA-48A/preOXA-48B for *bla*<sub>OXA-48</sub> and *bla*<sub>OXA-181</sub> (13). The PCR products were run on a 1% agarose gel (Lonza, Rockland, ME, USA) and gel purified using a NucleoSpin gel and PCR cleanup kit (Macherey-Nagel, Düren, Germany) before cloning into the pCR-BluntII-TOPO vector and transformation into *E. coli* TOP10 according to the manufacturer's instruction (Invitrogen, CA, USA). Transformants were selected on Luria-Bertani (LB) agar plates (Becton Dickinson) containing 50 mg/liter kanamycin (Sigma-Aldrich, St. Louis, MO, USA). Verification of the cloned DNA insert was performed by PCR and Sanger sequencing (BigDye, version 3.1, technology; Applied Biosystems, CA, USA) using M13 forward (5'-GTAAAACGACGGCCAG-3') and reverse (5'-CAGGAAACAGCTATGAC-3') primers.

**Kinetic analysis.** All kinetic experiments for  $\beta$ -lactam substrates were performed using UV spectroscopy with a SpectraMax M2e spectrophotometer (Molecular Devices) at 25°C in triplicate in 100 mM sodium phosphate buffer (Sigma-Aldrich, St. Louis, MO, USA), pH 7.0, supplemented with 50 mM sodium bicarbonate (Merck Millipore, Darmstadt, Germany) and 0.2 mg/ml bovine serum albumin (Sigma-Aldrich, St. Louis, MO, USA) (30). Hydrolysis measurements were performed with ampicillin ( $\Delta\epsilon_{235} = -820 \text{ M}^{-1} \text{ cm}^{-1}$ , 0.4 to 112.5  $\mu$ M [Sigma-Aldrich]; 0.1 nM OXA-436), benzylpenicillin ( $\Delta\epsilon_{235} = -775 \text{ M}^{-1} \text{ cm}^{-1}$ , 222 to 3,000  $\mu$ M [Panpharma]; 0.1 nM OXA-436), cefepime ( $\Delta\epsilon_{260} = -10,000 \text{ M}^{-1} \text{ cm}^{-1}$ , 14 to 462  $\mu$ M [European Pharmacopoeia Reference Standards]; 1 nM OXA-436), cefotaxime ( $\Delta\epsilon_{260} = -7,500 \text{ M}^{-1} \text{ cm}^{-1}$ , 2.5 to 217.3  $\mu$ M [Tokyo Chemical Industry Co., Ltd.]; 1 nM OXA-436), ceftazidime ( $\Delta\epsilon_{260} = -9,000 \text{ M}^{-1} \text{ cm}^{-1}$ , 3.9 to 500  $\mu$ M [Sigma-Aldrich]; 1 nM OXA-436), ertapenem ( $\Delta\epsilon_{300} = -6,920 \text{ M}^{-1} \text{ cm}^{-1}$ , 7.8 to 1,000  $\mu$ M [Merck Sharp & Dohme]; 5 nM OXA-436), imipenem ( $\Delta\epsilon_{300 \text{ nm}} = -9,000 \text{ M}^{-1} \text{ cm}^{-1}$ , 0.4 to 50  $\mu$ M [European Pharmacopoeia Reference Standards]; 1 nM OXA-436), meropenem ( $\Delta\epsilon_{300} = -6,500 \text{ M}^{-1} \text{ cm}^{-1}$ , 0.4 to 50  $\mu$ M [Sigma-Aldrich]; 5 nM OXA-436), and temocillin ( $\Delta\epsilon_{235} = -660 \text{ M}^{-1} \text{ cm}^{-1}$ , 3.9 to 500  $\mu$ M [Eumedica Pharmaceuticals]; 5 nM OXA-436). Kinetic parameters were determined by nonlinear regression of the steady-state velocities as a function of the substrate concentrations using the Michaelis-Menten equation in Prism (version 6) software (GraphPad Software, CA, USA).

**Design of *bla*<sub>OXA-436</sub> PCR.** Primers for the specific PCR detection of a 672-bp *bla*<sub>OXA-436</sub> fragment, *bla*<sub>OXA-436</sub> forward (5'-TCGGTGTGTGTGATGTTGA-3') and *bla*<sub>OXA-436</sub> reverse (5'-GTCATCCAGTTCGATCCA-3'), were designed using CLCbio's Main Workbench (version 7.5.1; Qiagen). A Qiagen multiplex PCR kit (Qiagen, Venlo, the Netherlands) was used for master mix preparation, and PCR conditions were initial

heat activation at 94°C for 15 min and 26 cycles of denaturation for 30 s at 94°C, annealing for 90 s at 58°C, and elongation for 60 s at 72°C, followed by a final elongation step of 10 min at 72°C.

**In vitro conjugation experiments.** *In vitro* conjugation experiments were performed using the sodium azide-resistant strain *E. coli* J53A3R as the recipient and *E. asburiae* AMA 497, *C. freundii* AMA 754, *K. pneumoniae* AMA 782, and *E. asburiae* AMA 810 as the donor strains. The recipient and donor strains were grown overnight in 50 ml Luria Bertani (LB) broth (with shaking at 120 rpm and 35°C). For the donor strains, LB broth was supplemented with 1 mg/liter ceftriaxone (Roche, Hvidovre, Denmark). After overnight incubation, 100  $\mu$ l of the culture was added to 10 ml fresh LB broth and regrown without shaking at 35°C to a turbidity equivalent to that of an approximately 1.0 McFarland standard. Donor and recipient cells were subsequently mixed at a 1:1 ratio. Two hundred microliters of the mixed culture was added onto three separate 0.45- $\mu$ m-pore-size nitrocellulose MF membrane filters (Merck Millipore Ltd., Cork, Ireland) placed on 5% blood agar plates (SSI Diagnostica, Hillerød, Denmark), and the plates were incubated overnight at 35°C. In addition, the mixed culture was left for liquid mating overnight at both room temperature and 35°C. After overnight incubation, the membrane filters were transferred to 5 ml 0.9% saline and vortexed. One hundred microliters of the 0.9% saline suspension with membrane filters and 100  $\mu$ l of the resulting liquid mating culture were spread on LB agar plates supplemented with either 2 mg/liter ceftriaxone plus 100 mg/liter sodium azide (SSI Diagnostica, Hillerød, Denmark) or 8 mg/liter gentamicin (Sandoz, Holzkirchen, Germany) plus 100 mg/liter sodium azide. After overnight incubation at 35°C, putative transconjugant colonies were subcultured, and the successful transfer of *bla*<sub>OXA-436</sub> was subsequently confirmed by PCR as described above combined with species identification using MALDI-TOF MS (Bruker Daltonik). For confirmatory purposes, one representative transconjugant per donor-recipient combination was subjected to WGS analysis as described above.

**Accession number(s).** WGS data from the isolates have been deposited at the National Center for Biotechnology Information (NCBI) under BioProject [PRJNA297498](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA297498), and the annotated sequence of plasmid pOXA436 has been deposited in GenBank under accession number [KY863418](https://www.ncbi.nlm.nih.gov/nuclseq/KY863418). Annotated contigs harboring *bla*<sub>OXA-436</sub> have been deposited in GenBank (GenBank accession numbers [KT959103](https://www.ncbi.nlm.nih.gov/nuclseq/KT959103) to [KT959108](https://www.ncbi.nlm.nih.gov/nuclseq/KT959108)).

## ACKNOWLEDGMENTS

Karin Sixhøj Pedersen is thanked for her excellent technical assistance. Kim Ng is thanked for his excellent help with the uploading of genome data to NCBI. The curators of the Lahey Clinic database on  $\beta$ -lactamases (<http://www.lahey.org/Studies/>) are acknowledged for assigning the new allele number for OXA-436. AstraZeneca is thanked for providing avibactam for the study. Coris BioConcept is thanked for providing the OXA-48 K-SeT immunochromatographic test.

The Pacific Biosciences sequencing service was provided by the Norwegian Sequencing Centre ([www.sequencing.uio.no](http://www.sequencing.uio.no)), a national technology platform hosted by the University of Oslo and supported by the Functional Genomics and the Infrastructure programs of the Research Council of Norway and the Southeastern Regional Health Authorities. This publication made use of the *Citrobacter freundii* MLST website (<http://pubmlst.org/cfreundii/>), developed by Keith Jolley and sited at the University of Oxford. The development of this site has been funded by the Wellcome Trust. Part of this work was supported by the Danish Ministry of Health as part of The Integrated Surveillance of ESBL/AmpC-producing *E. coli* and Carbapenemase-Producing Bacteria.

We declare that we have no conflicts of interests.

## REFERENCES

- Evans BA, Amyes SG. 2014. OXA  $\beta$ -lactamases. Clin Microbiol Rev 27: 241–263. <https://doi.org/10.1128/CMR.00117-13>.
- Poirel L, Naas T, Nordmann P. 2010. Diversity, epidemiology, and genetics of class D  $\beta$ -lactamases. Antimicrob Agents Chemother 54:24–38. <https://doi.org/10.1128/AAC.01512-08>.
- Poirel L, Heritier C, Tolun V, Nordmann P. 2004. Emergence of oxacillinase-mediated resistance to imipenem in *Klebsiella pneumoniae*. Antimicrob Agents Chemother 48:15–22. <https://doi.org/10.1128/AAC.48.1.15-22.2004>.
- Nordmann P, Poirel L. 2014. The difficult-to-control spread of carbapenemase producers among *Enterobacteriaceae* worldwide. Clin Microbiol Infect 20:821–830. <https://doi.org/10.1111/1469-0691.12719>.
- Sampaio JL, Ribeiro VB, Campos JC, Rozales FP, Magagnin CM, Falci DR, da Silva RC, Dalarosa MG, Luz DI, Vieira FJ, Antchev LC, Barth AL, Zavascki AP. 2014. Detection of OXA-370, an OXA-48-related class D  $\beta$ -lactamase, in *Enterobacter hormaechei* from Brazil. Antimicrob Agents Chemother 58:3566–3567. <https://doi.org/10.1128/AAC.02510-13>.
- Dortet L, Oueslati S, Jeannot K, Tande D, Naas T, Nordmann P. 2015. Genetic and biochemical characterization of OXA-405, an OXA-48-type extended-spectrum  $\beta$ -lactamase without significant carbapenemase activity. Antimicrob Agents Chemother 59:3823–3828. <https://doi.org/10.1128/AAC.05058-14>.
- Potron A, Poirel L, Rondinaud E, Nordmann P. 2013. Intercontinental spread of OXA-48  $\beta$ -lactamase-producing *Enterobacteriaceae* over a 11-year period, 2001 to 2011. Euro Surveill 18(31):pii=20549. <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20549>.
- Carattoli A, Seiffert SN, Schwendener S, Perreten V, Endimiani A. 2015. Differentiation of IncL and IncM plasmids associated with the spread of clinically relevant antimicrobial resistance. PLoS One 10:e0123063. <https://doi.org/10.1371/journal.pone.0123063>.
- Zong Z. 2012. Discovery of *bla*<sub>OXA-199</sub>, a chromosome-based *bla*<sub>OXA-48</sub>-like variant, in *Shewanella xiamenensis*. PLoS One 7:e48280. <https://doi.org/10.1371/journal.pone.0048280>.
- Poirel L, Heritier C, Nordmann P. 2004. Chromosome-encoded Ambler



- class D  $\beta$ -lactamase of *Shewanella oneidensis* as a progenitor of carbapenem-hydrolyzing oxacillinase. *Antimicrob Agents Chemother* 48: 348–351. <https://doi.org/10.1128/AAC.48.1.348-351.2004>.
11. Potron A, Poirel L, Nordmann P. 2011. Origin of OXA-181, an emerging carbapenem-hydrolyzing oxacillinase, as a chromosomal gene in *Shewanella xiamenensis*. *Antimicrob Agents Chemother* 55:4405–4407. <https://doi.org/10.1128/AAC.00681-11>.
  12. Oueslati S, Nordmann P, Poirel L. 2015. Heterogeneous hydrolytic features for OXA-48-like  $\beta$ -lactamases. *J Antimicrob Chemother* 70: 1059–1063. <https://doi.org/10.1093/jac/dku524>.
  13. Poirel L, Castanheira M, Carrer A, Rodriguez CP, Jones RN, Smayevsky J, Nordmann P. 2011. OXA-163, an OXA-48-related class D  $\beta$ -lactamase with extended activity toward expanded-spectrum cephalosporins. *Antimicrob Agents Chemother* 55:2546–2551. <https://doi.org/10.1128/AAC.00022-11>.
  14. Gomez S, Pasteran F, Faccone D, Bettiol M, Veliz O, De Belder D, Rapoport M, Gatti B, Petroni A, Corso A. 2013. Inpatient emergence of OXA-247: a novel carbapenemase found in a patient previously infected with OXA-163-producing *Klebsiella pneumoniae*. *Clin Microbiol Infect* 19:E233–E235. <https://doi.org/10.1111/1469-0691.12142>.
  15. Potron A, Nordmann P, Lefeuvre E, Al Maskari Z, Al Rashdi F, Poirel L. 2011. Characterization of OXA-181, a carbapenem-hydrolyzing class D  $\beta$ -lactamase from *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 55:4896–4899. <https://doi.org/10.1128/AAC.00481-11>.
  16. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, Larsen MV. 2012. Identification of acquired antimicrobial resistance genes. *J Antimicrob Chemother* 67:2640–2644. <https://doi.org/10.1093/jac/dks261>.
  17. Olsen I. 2015. New promising  $\beta$ -lactamase inhibitors for clinical use. *Eur J Clin Microbiol Infect Dis* 34:1303–1308. <https://doi.org/10.1007/s10096-015-2375-0>.
  18. Huang TD, Poirel L, Bogaerts P, Berhin C, Nordmann P, Glupczynski Y. 2014. Temocillin and piperacillin/tazobactam resistance by disc diffusion as antimicrobial surrogate markers for the detection of carbapenemase-producing *Enterobacteriaceae* in geographical areas with a high prevalence of OXA-48 producers. *J Antimicrob Chemother* 69:445–450. <https://doi.org/10.1093/jac/dkt367>.
  19. Knox J, Jadhav S, Sevier D, Agyekum A, Whipp M, Waring L, Iredell J, Palombo E. 2014. Phenotypic detection of carbapenemase-producing *Enterobacteriaceae* by use of matrix-assisted laser desorption/ionization–time of flight mass spectrometry and the Carba NP test. *J Clin Microbiol* 52:4075–4077. <https://doi.org/10.1128/JCM.02121-14>.
  20. Österblad M, Hakanen AJ, Jalava J. 2014. Evaluation of the Carba NP test for carbapenemase detection. *Antimicrob Agents Chemother* 58: 7553–7556. <https://doi.org/10.1128/AAC.02761-13>.
  21. Garcia-Fernandez A, Carattoli A. 2010. Plasmid double locus sequence typing for IncHI2 plasmids, a subtyping scheme for the characterization of IncHI2 plasmids carrying extended-spectrum  $\beta$ -lactamase and quinolone resistance genes. *J Antimicrob Chemother* 65:1155–1161. <https://doi.org/10.1093/jac/dkq101>.
  22. Gilmour MW, Thomson NR, Sanders M, Parkhill J, Taylor DE. 2004. The complete nucleotide sequence of the resistance plasmid R478: defining the backbone components of incompatibility group H conjugative plasmids through comparative genomics. *Plasmid* 52:182–202. <https://doi.org/10.1016/j.plasmid.2004.06.006>.
  23. Chen YT, Liao TL, Liu YM, Lauderdale TL, Yan JJ, Tsai SF. 2009. Mobilization of *qnrB2* and *ISCR1* in plasmids. *Antimicrob Agents Chemother* 53:1235–1237. <https://doi.org/10.1128/AAC.00970-08>.
  24. Zhai Y, He Z, Kang Y, Yu H, Wang J, Du P, Zhang Z, Hu S, Gao Z. 2016. Complete nucleotide sequence of pH11, an IncHI2 plasmid conferring multi-antibiotic resistance and multi-heavy metal resistance genes in a clinical *Klebsiella pneumoniae* isolate. *Plasmid* 86:26–31. <https://doi.org/10.1016/j.plasmid.2016.04.001>.
  25. Liu C, Qin S, Xu H, Xu L, Zhao D, Liu X, Lang S, Feng X, Liu HM. 2015. New Delhi metallo- $\beta$ -lactamase 1 (NDM-1), the dominant carbapenemase detected in carbapenem-resistant *Enterobacter cloacae* from Henan Province, China. *PLoS One* 10:e0135044. <https://doi.org/10.1371/journal.pone.0135044>.
  26. Konstantinidis KT, Serres MH, Romine MF, Rodrigues JL, Auchtung J, McCue LA, Lipton MS, Obraztsova A, Giometti CS, Nealson KH, Fredrickson JK, Tiedje JM. 2009. Comparative systems biology across an evolutionary gradient within the *Shewanella* genus. *Proc Natl Acad Sci U S A* 106:15909–15914. <https://doi.org/10.1073/pnas.0902000106>.
  27. Dabos MJ, Potron A, Dortet A, Iorga L, Bonnin B, Naas RT. 2017. Genetic and biochemical characterization of OXA-535, a novel OXA-48-like enzyme progenitor of OXA-436 from *Shewanella bicestris*, abstr P0233. Abstr 27th Eur Congr Clin Microbiol Infect Dis, Vienna, Austria.
  28. Docquier JD, Calderone V, De Luca F, Benvenuti M, Giuliani F, Bellucci L, Tafi A, Nordmann P, Botta M, Rossolini GM, Mangani S. 2009. Crystal structure of the OXA-48  $\beta$ -lactamase reveals mechanistic diversity among class D carbapenemases. *Chem Biol* 16:540–547. <https://doi.org/10.1016/j.chembiol.2009.04.010>.
  29. Antonelli A, D'Andrea MM, Vaggelli G, Docquier JD, Rossolini GM. 2015. OXA-372, a novel carbapenem-hydrolyzing class D  $\beta$ -lactamase from a *Citrobacter freundii* isolated from a hospital wastewater plant. *J Antimicrob Chemother* 70:2749–2756. <https://doi.org/10.1093/jac/dkv181>.
  30. Antunes NT, Lamoureaux TL, Toth M, Stewart NK, Frase H, Vakulenko SB. 2014. Class D  $\beta$ -lactamases: are they all carbapenemases? *Antimicrob Agents Chemother* 58:2119–2125. <https://doi.org/10.1128/AAC.02522-13>.
  31. Rodionov MA, Blundell TL. 1998. Sequence and structure conservation in a protein core. *Proteins* 33:358–366. [https://doi.org/10.1002/\(SICI\)1097-0134\(199811\)33:3<358::AID-PROT5>3.0.CO;2-0](https://doi.org/10.1002/(SICI)1097-0134(199811)33:3<358::AID-PROT5>3.0.CO;2-0).
  32. Samuelsen Ø, Naseer U, Karah N, Lindemann PC, Kanestrøm A, Leegaard TM, Sundsfjord A. 2013. Identification of *Enterobacteriaceae* isolates with OXA-48 and coproduction of OXA-181 and NDM-1 in Norway. *J Antimicrob Chemother* 68:1682–1685. <https://doi.org/10.1093/jac/dkt058>.
  33. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, tenth edition: approved standard M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
  34. Dortet L, Brechard L, Poirel L, Nordmann P. 2014. Impact of the isolation medium for detection of carbapenemase-producing *Enterobacteriaceae* using an updated version of the Carba NP test. *J Med Microbiol* 63: 772–776. <https://doi.org/10.1099/jmm.0.071340-0>.
  35. Hansen F, Johansen HK, Ostergaard C, Arpi M, Hansen DS, Littauer P, Holm A, Heltberg O, Schumacher H, Fuursted K, Lykke MA, Tønning B, Hammerum AM, Justesen US. 2014. Characterization of carbapenem nonsusceptible *Pseudomonas aeruginosa* in Denmark: a nationwide, prospective study. *Microb Drug Resist* 20:22–29. <https://doi.org/10.1089/mdr.2013.0085>.
  36. Woodford N, Tierno PM, Jr, Young K, Tysall L, Palepou MF, Ward E, Painter RE, Suber DF, Shungu D, Silver LL, Inglima K, Kornblum J, Livermore DM. 2004. Outbreak of *Klebsiella pneumoniae* producing a new carbapenem-hydrolyzing class A  $\beta$ -lactamase, KPC-3, in a New York medical center. *Antimicrob Agents Chemother* 48:4793–4799. <https://doi.org/10.1128/AAC.48.12.4793-4799.2004>.
  37. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25:1754–1760. <https://doi.org/10.1093/bioinformatics/btp324>.
  38. Delcher AL, Phillippy A, Carlton J, Salzberg SL. 2002. Fast algorithms for large-scale genome alignment and comparison. *Nucleic Acids Res* 30: 2478–2483. <https://doi.org/10.1093/nar/30.11.2478>.
  39. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. 2013. MEGA6: molecular evolutionary genetics analysis version 6.0. *Mol Biol Evol* 30: 2725–2729. <https://doi.org/10.1093/molbev/mst197>.
  40. Larsen MV, Cosentino S, Rasmussen S, Friis C, Hasman H, Marvig RL, Jelsbak L, Sicheritz-Ponten T, Ussery DW, Aarestrup FM, Lund O. 2012. Multilocus sequence typing of total-genome-sequenced bacteria. *J Clin Microbiol* 50:1355–1361. <https://doi.org/10.1128/JCM.06094-11>.
  41. Carattoli A, Zankari E, Garcia-Fernandez A, Voldby Larsen M, Lund O, Villa L, Møller Aarestrup F, Hasman H. 2014. *In silico* detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 58:3895–3903. <https://doi.org/10.1128/AAC.02412-14>.
  42. Paauw A, Caspers MP, Schuren FH, Leverstein-van Hall MA, Deletoile A, Montijn RC, Verhoef J, Fluit AC. 2008. Genomic diversity within the *Enterobacter cloacae* complex. *PLoS One* 3:e3018. <https://doi.org/10.1371/journal.pone.0003018>.
  43. Stamatakis A. 2014. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. *Bioinformatics* 30:1312–1313. <https://doi.org/10.1093/bioinformatics/btu033>.
  44. Katoh K, Rozewicki J, Yamada KD. 6 September 2017. MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization. *Brief Bioinform*. <https://doi.org/10.1093/bib/bbx108>.
  45. Robert X, Gouet P. 2014. Deciphering key features in protein structures



- with the new ENDScript server. *Nucleic Acids Res* 42:W320–W324. <https://doi.org/10.1093/nar/gku316>.
46. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30:2068–2069. <https://doi.org/10.1093/bioinformatics/btu153>.
47. Stothard P, Wishart DS. 2005. Circular genome visualization and exploration using CGView. *Bioinformatics* 21:537–539. <https://doi.org/10.1093/bioinformatics/bti054>.
48. Lund BA, Leiros HK, Bjerga GE. 2014. A high-throughput, restriction-free cloning and screening strategy based on *ccdB*-gene replacement. *Microb Cell Fact* 13:38. <https://doi.org/10.1186/1475-2859-13-38>.
49. Borra PS, Samuelson Ø, Spencer J, Walsh TR, Lorentzen MS, Leiros HK. 2013. Crystal structures of *Pseudomonas aeruginosa* GIM-1: active-site plasticity in metallo- $\beta$ -lactamases. *Antimicrob Agents Chemother* 57: 848–854. <https://doi.org/10.1128/AAC.02227-12>.
50. Studier FW. 2005. Protein production by auto-induction in high density shaking cultures. *Protein Expr Purif* 41:207–234. <https://doi.org/10.1016/j.pep.2005.01.016>.
51. Giuliani F, Docquier JD, Riccio ML, Pagani L, Rossolini GM. 2005. OXA-46, a new class D  $\beta$ -lactamase of narrow substrate specificity encoded by a *bla*<sub>VIM-1</sub>-containing integron from a *Pseudomonas aeruginosa* clinical isolate. *Antimicrob Agents Chemother* 49:1973–1980. <https://doi.org/10.1128/AAC.49.5.1973-1980.2005>.